Axol Bioscience Ltd.

Axol Bioscience Ltd. is a biotechnology startup based in the United Kingdom, specializing in iPSC technology to create advanced models for drug discovery. With a decade of experience, they supply human iPSC-derived cells and offer laboratory services to support drug discovery in neurodegenerative, neuroinflammatory, and cardiotoxicity areas. Their expertise in iPSC products and services has positioned them as leaders in supplying top Biopharma institutions and drug discovery companies with high-quality in vitro models and custom lab services. Their capabilities also extend to supporting advanced in vitro disease models and supply volume for organ-on-a-chip devices and microfluidics platforms, demonstrating their commitment to pioneering the utility of iPSCs for research and drug discovery. At the latest funding round in April 2022, Axol Bioscience Ltd. secured a substantial £3.20M Venture Round investment from Par Equity, Scottish Enterprise, Calculus Capital, and Meltwind Advisory. This funding is expected to bolster their position as world leaders in iPSC technology and drive further innovation in creating better, safer therapies for various diseases within the biopharmaceutical and biotechnology industries.